{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:36:21Z","timestamp":1792028181536,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00125-019-4839-8","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T14:03:31Z","timestamp":1552485811000},"page":"926-938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program"],"prefix":"10.1007","volume":"62","author":[{"given":"David R.","family":"Matthews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Fulcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Hiatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Fabbrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kavalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"issue":"9896","key":"4839_CR1","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941\u2013950. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)60683-2","journal-title":"Lancet"},{"issue":"7","key":"4839_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"2","key":"4839_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","volume":"166","author":"B Neal","year":"2013","unstructured":"Neal B, Perkovic V, de Zeeuw D et al (2013) Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J 166(2):217\u2013223 e211. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2013.05.007","journal-title":"Am Heart J"},{"issue":"3","key":"4839_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/dom.12829","volume":"19","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR et al (2017) Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 19(3):387\u2013393. \n                    https:\/\/doi.org\/10.1111\/dom.12829","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"4839_CR5","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/dom.12924","volume":"19","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 19(7):926\u2013935. \n                    https:\/\/doi.org\/10.1111\/dom.12924","journal-title":"Diabetes Obes Metab"},{"key":"4839_CR6","unstructured":"Janssen Inc (2017) Product monograph - C. Available from \n                    https:\/\/www.drugs.com\/monograph\/canagliflozin.html\n                    \n                  . Accessed 26 June 2018"},{"key":"4839_CR7","unstructured":"STEGLATRO\u2122 [package insert] (2017) Whitehouse Station, NJ: Merck Sharp & Dohme Corp"},{"issue":"3","key":"4839_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/dom.13115","volume":"20","author":"Z Yuan","year":"2018","unstructured":"Yuan Z, Defalco FJ, Ryan PB et al (2018) Risk of lower extremity amputations in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors in the United States: a retrospective cohort study. Diabetes Obes Metab 20(3):582\u2013589. \n                    https:\/\/doi.org\/10.1111\/dom.13115","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"4839_CR9","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Iliev H, Pfarr E, Zinman B (2018) Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41(1):e4\u2013e5. \n                    https:\/\/doi.org\/10.2337\/dc17-1551","journal-title":"Diabetes Care"},{"key":"4839_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","volume":"140","author":"K Radholm","year":"2018","unstructured":"Radholm K, Wu JH, Wong MG et al (2018) Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - a systematic review. Diabetes Res Clin Pract 140:118\u2013128. \n                    https:\/\/doi.org\/10.1016\/j.diabres.2018.03.027","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"4839_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000484633","volume":"46","author":"MJ Jardine","year":"2017","unstructured":"Jardine MJ, Mahaffey KW, Neal B et al (2017) The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46(6):462\u2013472. \n                    https:\/\/doi.org\/10.1159\/000484633","journal-title":"Am J Nephrol"},{"issue":"11","key":"4839_CR12","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"PB Ryan","year":"2018","unstructured":"Ryan PB, Buse JB (2018) Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 20(11):2585\u20132597. \n                    https:\/\/doi.org\/10.1111\/dom.13424","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"4839_CR13","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","volume":"137","author":"JA Udell","year":"2018","unstructured":"Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N (2018) Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). Circulation 137(14):1450\u20131459. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031227","journal-title":"Circulation"},{"issue":"6","key":"4839_CR14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/dom.13255","volume":"20","author":"C Khouri","year":"2018","unstructured":"Khouri C, Cracowski JL, Roustit M (2018) SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? Diabetes Obes Metab 20(6):1531\u20131534. \n                    https:\/\/doi.org\/10.1111\/dom.13255","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"4839_CR15","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","volume":"5","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Avogaro A (2017) SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol 5(9):680\u2013681. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(17)30257-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4839_CR16","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstrom H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365","journal-title":"BMJ"},{"key":"4839_CR17","unstructured":"U.S. Food & Drug Administration (2017) FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Available from \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM558427.pdf\n                    \n                  . Accessed 9 August 2017"},{"key":"4839_CR18","unstructured":"European Medicines Agency (2017) PRAC assessment report. Available from \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SGLT2_inhibitors_Canagliflozin_20\/European_Commission_final_decision\/WC500227102.pdf\n                    \n                  . Accessed 16 June 2017"},{"issue":"22","key":"4839_CR19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"7","key":"4839_CR20","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","volume":"34","author":"S Kohler","year":"2017","unstructured":"Kohler S, Zeller C, Iliev H, Kaspers S (2017) Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther 34(7):1707\u20131726. \n                    https:\/\/doi.org\/10.1007\/s12325-017-0573-0","journal-title":"Adv Ther"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4839-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-019-4839-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4839-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T20:15:19Z","timestamp":1583871319000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-019-4839-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4839"],"URL":"https:\/\/doi.org\/10.1007\/s00125-019-4839-8","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"assertion":[{"value":"15 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DRM reports receiving support from Janssen for his role as co-chair of the CANVAS Program steering committee. QL reports being a full-time employee of the George Institute for Global Health. VP reports receiving personal fees for advisory boards or scientific presentations from Retrophin, Janssen, Merck and Servier, serving on steering committees for trials funded by AbbVie, Boehringer Ingelheim, GlaxoSmithKline, Janssen and Pfizer and participating in scientific presentations\/advisory boards with AbbVie, Astellas, Astra Zeneca, Bayer, Baxter, Bristol-Myers Squibb, Boehringer Ingelheim, Durect, Eli Lilly, Gilead, GlaxoSmithKline, Novartis, Novo Nordisk, Pharmalink, Relypsa, Sanofi and Vitae, with all fees paid to his employer. KWM reports receiving grants from Afferent, Amgen, Apple Inc., AstraZeneca, Cardiva Medical, Daiichi, Ferring, Google (Verily), Johnson & Johnson, Luitpold, Medtronic, Merck, Novartis, Sanofi, St Jude and Tenax, receiving personal fees from Ablynx, AstraZeneca, Baim Institute, Boehringer Ingelheim, Bristol-Myers Squibb, Cardiometabolic Health Congress, Elsevier, GlaxoSmithKline, Johnson & Johnson, Medscape, Merck, Mitsubishi, Myokardia, Novartis, Oculeve, Portola, Radiometer, Springer Publishing, Theravance, University of California San Francisco and WebMD and having equity in BioPrint Fitness. DdZ reports serving on advisory boards and\/or as a speaker for Bayer, Boehringer Ingelheim, Fresenius, Mundipharma and Mitsubishi-Tanabe, being a steering committee member and\/or speaker for AbbVie and Janssen and serving on Data Safety and Monitoring Committees for Bayer. GF reports receiving grants from Novo Nordisk and personal fees from Janssen, Novo Nordisk, Boehringer Ingelheim and Merck Sharp & Dohme. MD, EF, MK and ML report being full-time employees of Janssen Research & Development, LLC. MK reports holding stock in Johnson & Johnson. WRH reports receiving grants from Janssen and Bayer. MN reports receiving salary support from CPC Research. BN reports receiving grants and travel costs related to presentation of data from Janssen and serving on advisory boards for Janssen, with any consultancy, honoraria or travel support paid to his institution. No other potential conflicts of interest relevant to this article are reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}}]}}